Clinical Trials Browser

Has results × Graft vs Host Disease × thymoglobulin × Clear all

NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

DermatologicLymphoidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01471444 2021-12-16

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 3 Completed

256 enrolled 13 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00813124 2021-02-11

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Phase 2 Completed

24 enrolled 8 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00822770 2020-10-14

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Phase 1/2 Completed

47 enrolled 8 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00506948 2020-09-24

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2 Terminated

13 enrolled 5 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02877082 2018-04-30

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Phase 2 Terminated

5 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT01390402 2016-02-03

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Phase 2 Completed

6 enrolled 3 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Terminated

8 enrolled 11 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis